BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1609034)

  • 21. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
    Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
    Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schizophrenia: gender, family risk, and plasma homovanillic acid.
    Dávila R; Zumárraga M; González-Torres MA; Andía I; Zamalloa MI; Basterreche E; Guimón J; Friedhoff AJ
    Am J Med Genet; 1995 Apr; 60(2):154-6. PubMed ID: 7485251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
    Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
    Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
    Chang WH; Chen TY; Lin SK; Lung FW; Lin WL; Hu WH; Yeh EK
    Biol Psychiatry; 1990 Mar; 27(5):510-8. PubMed ID: 2310806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effects of mental stress on plasma homovanillic acid in schizophrenia and normal controls.
    Sumiyoshi T; Saitoh O; Yotsutsuji T; Itoh H; Kurokawa K; Kurachi M
    Neuropsychopharmacology; 1999 Apr; 20(4):365-9. PubMed ID: 10088137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients.
    Seiler W; Wetzel H; Hillert A; Schöllnhammer G; Benkert O; Hiemke C
    Exp Clin Endocrinol; 1994; 102(4):326-33. PubMed ID: 7813605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
    Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
    Davidson M; Losonczy MF; Mohs RC; Lesser JC; Powchik P; Freed LB; Davis BM; Mykytyn VV; Davis KL
    Neuropsychopharmacology; 1987 Dec; 1(1):17-23. PubMed ID: 3509064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
    Brown AS; Gewirtz G; Harkavy-Friedman J; Cooper T; Brébion G; Amador XF; Malaspina D; Gorman JM
    Neuropsychopharmacology; 1997 Nov; 17(5):317-25. PubMed ID: 9348547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol response and plasma catecholamines and their metabolites.
    Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
    Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women.
    Glazer WM; Naftolin F; Moore DC; Bowers MB; MacLusky NJ
    Psychoneuroendocrinology; 1983; 8(4):429-34. PubMed ID: 6144123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
    Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
    Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
    Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
    Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma homovanillic acid and prolactin in Huntington's disease.
    Markianos M; Panas M; Kalfakis N; Vassilopoulos D
    Neurochem Res; 2009 May; 34(5):917-22. PubMed ID: 18841471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma homovanillic acid as a predictor of response to neuroleptics.
    Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
    Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.